Cellectis (CLLS) Divestments (2022 - 2023)
Cellectis (CLLS) posted quarterly Divestments of -$18000.0 for Q2 2023, up 95.98% year-over-year from -$9184.5 in Q2 2022, and down 118.56% quarter-over-quarter from $97000.0 in Q1 2023.
Cellectis (CLLS) Divestments (2022 - 2023) Analysis & Trends
Cellectis' Divestments history runs 2 years deep, the most recent figure standing at -$18000.0 for Q2 2023.
- In Q2 2023, Divestments rose 95.98% year-over-year to -$18000.0; the TTM figure through Dec 2023 stood at $79000.0 (up 117.71% YoY), while the FY2023 annual figure was $79000.0, up 117.71% from the prior year.
- Divestments for Q2 2023 stood at -$18000.0, down from $97000.0 in the prior quarter.
- The five-year high for Divestments was $177000.0 in Q3 2022, with the low at -$448000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 9.82 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -13.21 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -18,000.00 |
| Mar 31, 2023 | 97,000.00 |
| Dec 31, 2022 | 121,000.00 |
| Sep 30, 2022 | 177,000.00 |
| Jun 30, 2022 | -448,000.00 |
| Mar 31, 2022 | -296,000.00 |